GLP ‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial
Authors' conclusion
GLP-1RAs reduced MACE risk across populations, with greater relative risk reduction in Asian populations and broadly similar benefits in Black or African American and White populations.
Study context
- Population
- Adults with T2D or overweight/obesity in randomized placebo-controlled GLP-1 RA trials reporting race-stratified major adverse cardiovascular events (MACE)9 trials
- Participants
- 8,164 / 4,036 / 62,503
- Comparison
- GLP-1 RA vs placebo, by Asian, Black or African American and White populations
- Asiann = 8,164
- Black or African Americann = 4,036
- Whiten = 62,503
- Outcome
- MACE:
- CV death
- Non-fatal MI
- Non-fatal stroke
Methodological detailsplacebo-controlled trials, random-effects meta-analysis, race-stratified analysis
- Placebo-controlled trials
- Random-effects meta-analysis
- Race-stratified analysis
Pooled result
As reported in the abstract
MACE by population (GLP-1RAs vs placebo)
Hazard ratio (95% CI)P value
AsianGLP-1RAsvs placebo in Asian populations
0.73(0.63–0.85)
P < 0.001WhiteGLP-1RAsvs placebo in White populations
0.86(0.81–0.91)
P < 0.001Black or African AmericanGLP-1RAsvs placebo; similar to White, not statistically significant
0.88(0.67–1.15)
P = 0.34- Asian vs White · significantly greater risk reduction in Asian populations
- RHR 0.84 (95% CI 0.71–0.98); P = 0.027
- Asian vs Black or African American · point estimates favouring Asian populations
- RHR 0.81 (95% CI 0.57–1.16); P = 0.25
Original publication
GLP ‐1 receptor agonists and cardiovascular outcomes in Asian, Black or African American, and White populations: An updated meta‐analysis including the SOUL trial. Diabetes Obes Metab. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →